These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 11363721)
21. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196 [TBL] [Abstract][Full Text] [Related]
22. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR; Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328 [TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618 [TBL] [Abstract][Full Text] [Related]
29. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD; AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693 [TBL] [Abstract][Full Text] [Related]
30. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD; HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766 [TBL] [Abstract][Full Text] [Related]
31. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
32. When to start therapy--and what to start with. Gallant JE Posit Aware; 1997; 8(1):22-3. PubMed ID: 11364093 [TBL] [Abstract][Full Text] [Related]
33. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM; Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093 [TBL] [Abstract][Full Text] [Related]
34. The case of the undetectable viral load. Jenny-Avital ER AIDS Clin Care; 1999 Mar; 11(3):20-1. PubMed ID: 11366207 [TBL] [Abstract][Full Text] [Related]
35. Viral load and response to treatment of HIV. Ioannidis JP; Cappelleri JC; Lau J N Engl J Med; 1996 Jun; 334(25):1671; author reply 1672-3. PubMed ID: 8628372 [No Abstract] [Full Text] [Related]
36. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF; Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392 [TBL] [Abstract][Full Text] [Related]
37. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038 [TBL] [Abstract][Full Text] [Related]
39. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023 [TBL] [Abstract][Full Text] [Related]
40. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN; AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]